logo
  

J.M. Smucker Posts Upbeat Q3 Results; Raises Full-year View- Quick Facts

Food and beverage maker The J.M. Smucker Co. (SJM) reported its third-quarter earnings of $261.5 million or $2.32 per share, up from $187.4 million or $1.64 per share in the comparable quarter last year.

Excluding items, adjusted earnings of $2.45 per share beat the average estimate of analysts polled by Thomson Reuters at $2.19 per share. Analysts' estimates typically exclude special items.

Net sales in the quarter also increased to $2.077 billion from $1.972 billion in the same quarter a year ago. The consensus estimate was for $2 billion.

Looking forward to the full year 2021, the company raised its earnings as well sales growth outlook.

The company now expects 2021 revenue growth of 2%, up from 0% - 1% rise provided earlier and adjusted earnings per share are expected between $8.70 and $8.90 compared with prior guidance of $8.35 to $8.65.

On average 13 analysts expect the company to report earnings of $8.73 per share on revenue of $7.83 billion for the period.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
CVS Health is set to recruit qualified candidates to fill 25,000 clinical and retail jobs during a one-day national career event on Friday, September 24. This will enable CVS to meet the high demand for pharmacists, pharmacy technicians, nurses, and retail store associates to support flu season, COVID-19 vaccinations and testing. Twitter, Inc. (TWTR) announced Monday that it has entered into a binding agreement to settle the consolidated class action lawsuit commenced in 2016 in the United States District Court for the Northern District of California. Under the terms of the proposed settlement, Twitter will pay $809.5 million... Drug major Pfizer has again expanded the earlier two recalls of its anti-smoking Drug Chantix (Varenicline) in the form of tablets, to now include all the lots, for the potential presence of nitrosamine impurity, N-Nitroso- varenicline, at or above the FDA interim acceptable intake limit (ADI), the U.S. Food and Drug Administration or FDA said in a statement.
Follow RTT